Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan

Video

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer

Diana Jaber;Natalie K Heater;Surbhi Warrior;Janice Lu, MD, PhD
July 3rd 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Radhika Appaya;Sarah Sammons, MD;Priyanka Sharma, MD;Yara Abdou;VK Gadi, MD, PhD;Taavy A. Miller;Spencer S. Langerman;Dominick Latremouille-Viau;Annie Guerin;Carmine Rossi;Emily McGovern;Gary Sopher;Vamsi Bollu;Natalia Bolotova;Şerban R. Iorga;Liz Santarsiero;Susan Dent, MD
June 30th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes

ONCOLOGY Staff
June 29th 2025
Article

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article